Factors shaping vaginal microbiota long-term community dynamics in young adult women

Tsukushi Kamiya^{1,*}, Nicolas Tessandier¹, Baptiste Elie^{1,2}, Claire Bernat^{2,3}, Vanina Boué², Sophie Grasset², Soraya Groc^{2,4}, Massilva Rahmoun², Christian Selinger^{2,5}, Michael S. Humphrys⁶, Marine Bonneau⁷, Christelle Graf⁷, Vincent Foulongne⁴, Jacques Reynes⁸, Vincent Tribout⁸, Michel Segondy⁴, Nathalie Boulle⁴, Jacques Ravel⁶, Carmen Lía Murall^{2,9}, and Samuel Alizon^{1,2,*}

¹Center for Interdisciplinary Research in Biology (CIRB), Collège de France, CNRS, INSERM, Université PSL, Paris, France
²MIVEGEC, CNRS, IRD, Université de Montpellier, France
³Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, Montpellier, France.
⁴PCCEI, Univ. Montpellier, Inserm, EFS, Montpellier, France
⁵Current address: Swiss Tropical and Public Health Institute, Basel, Switzerland
⁶Institute for Genomic Sciences, University of Baltimore, USA
⁷Department of Obstetrics and Gynaecology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
⁸Department of Infectious and Tropical Diseases, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
⁹National Microbiology Laboratory (NML), Montreal Public Health Agency of Canada (PHAC), Canada
*Corresponding authors: tsukushi.kamiya@college-de-france.fr,

samuel.alizon@college-de-france.fr

Abstract

1

The vaginal microbiota is known to affect women's health. Yet, there is a notable paucity 2 of high-resolution follow-up studies lasting several months, which would be required to 3 interrogate the long-term dynamics and associations with demographic and behavioural covariates. Here, we present a high-resolution longitudinal cohort of 125 women followed 5 for a median duration of 8.6 months, providing 11 samples per woman. Using a hierarchical 6 Bayesian Markov model, we characterised the patterns of vaginal microbiota community persistence and transition, simultaneously estimated the impact of 16 covariates and quan-8 tified individual variability among women. We showed that 'optimal' (Community State g Type (CST) I, II, and V) and 'sub-optimal' (CST III) communities are more stable over 10 time than 'non-optimal' (CST IV) ones. Furthermore, we found that some covariates most notably alcohol consumption — impacted the probability of shifting from one CST 12 to another. We performed counterfactual simulations to confirm that alterations of key 13 covariates, such as alcohol consumption, could shape the prevalence of different microbiota 14 communities in the population. Finally, our analyses indicated that there is a relatively 15 canalised pathway leading to the deterioration of vaginal microbiota communities, whereas 16 the paths to recovery can be highly individualised among women. In addition to providing 17 one of the first insights into vaginal microbiota dynamics over a year, our study showcases 18 a novel application of a hierarchical Bayesian Markov model to clinical cohort data with 19 many covariates. Our findings pave the way for an improved mechanistic understanding of 20

microbial dynamics in the vaginal environment and the development of novel preventative 21

22

and therapeutic strategies to improve vaginal health.

Introduction

Epithelia of the human body are host to a diverse array of microorganisms. These microorganisms are collectively referred to as microbiota and their compositions are tightly 25 associated with human health. In the human vaginal environment, the description of the 26 microbiota dates back to Albert Döderlein in 1892. Its composition has been demonstrated 27 to impact the acquisition risk of several sexually transmitted infections (STIs) [1], fertility 28 (especially in medically-assisted procreation procedures) [2], and general well-being [3]. 29

Vaginal microbiota communities comprise hundreds of species. To facilitate understanding, the variation in community composition is usually reduced to a handful of categories that capture key compositional signatures, such as the dominance of certain species or species evenness. This dimensionality reduction filters out noise in the data and facilitates the identification and visualisation of key patterns and relationships.

Potential drawbacks of reducing continuous variation include the risk of losing sub-35 the but meaningful signals within the microbiota, as less dominant or rare taxa may be 36 excluded despite their potential importance. Compared to the gut microbiota, however, 37 vaginal microbiota communities tend to be highly structured and are often dominated by 38 a small handful of species whose functional ecology is well-documented [4]. This contrasts 39 with the highly diverse gut microbiota, where defining discrete community types, such as 40 "enterotypes," remains contentious [5]. The high diversity and evenness in gut microbiota 41 introduce continuous variations that can be oversimplified by strict categorical clustering. 42

23

In contrast, vaginal microbiota composition aligns more naturally with categorical clustering, providing a robust understanding of key microbial patterns without significantly sacrificing interpretability.

One dimensionality reduction framework, i.e., community state types (CSTs), intro-46 duced by Ravel et al. [6], categorises vaginal microbial communities into five discrete state 47 types. The CSTs considered 'optimal' for health are dominated by *Lactobacillus* species; 48 Lactobacillus crispatus, L. gasseri, and L. jensenii for CST I, II, and V, respectively. Lac-49 tobacilli produce lactic acid and hydrogen peroxide, which create an acidic environment 50 that helps to inhibit the growth of harmful pathogens [7]. On the other end of the spec-51 trum, CST IV is the primary microbial context of bacterial vaginosis (BV), which elevates 52 the risk of STI acquisition and spontaneous preterm birth, and is associated with symp-53 toms such as malodor, discharge, and itching [4, 8]. This community is characterised by 54 a diverse assemblage of anaerobic bacterial species from the Gardnerella, Prevotella, and 55 Fannyhessea genera: recent classifications include sub-categories within CST IV (i.e., IV-A, 56 IV-B, IV-C), each with a distinct microbial profile [9]. Finally, CST III, characterised by a 57 dominance of L. iners, is considered 'sub-optimal' for women's health. While L. iners is a 58 member of the *Lactobacillus* genus, it is less effective at producing lactic acid and hydrogen 59 peroxide. As such, women with CST III tend to exhibit higher vaginal pH than those with 60 CST I and are more prone to experiencing adverse health consequences, including vaginal 61 infections [10]. 62

The CST classification represents a snapshot of the microbiota community at the time of 63

sampling that facilitates the examination of clinically relevant microbiota variations across ⁶⁴ time and women. The development of the modern pipeline — through meta-barcoding ⁶⁵ sequencing of 16S DNA and clustering algorithms [9] — allows for CST-typing with enhanced efficiency and reduced observer bias compared to conventional microscopy-based ⁶⁷ methods of vaginal microbiota community typing (e.g., Nugent score). ⁶⁸

The composition of vaginal microbiota is characteristically variable over both short 69 and long timescales [11]. For instance, vaginal microbiota shifts throughout a woman's life, 70 with prepubescent girls and postmenopausal women exhibiting lower levels of *Lactobacillus* 71 dominance compared to women of reproductive age, though their bacterial communities 72 are distinct from the CST IV typically seen during reproductive years [4]. On a short 73 timescale, daily CST fluctuations are observed in some women of reproductive age, while 74 others remain remarkably stable across menstrual cycles, suggesting that diverse factors 75 influence the dynamics of vaginal microbiota communities [12]. For example, menstruation 76 is a key driver of monthly dynamics, while clinical interventions such as antibiotics and 77 probiotics can cause temporary perturbations [4]. 78

A notable gap in the existing literature remains in the understanding of the long-term ⁷⁹ dynamics of vaginal microbiota in reproductive-aged women across several months. While ⁸⁰ some studies do follow this timespan, they focus on pregnancy-specific dynamics [13, 14], ⁸¹ have large intervals between samples (often exceeding three months) [15], or involve modest ⁸² sample sizes [16]. These limitations hinder our ability to fully understand the long-term ⁸³ patterns of CST stability and transitions in the general population of reproductive-aged ⁸⁴

women, and the influence of clinically relevant factors such as demography, lifestyle, sexual practices, and medication. 86

In this study, we introduce an original follow-up cohort of 125 women in Montpellier, France. Our cohort presents a high-resolution longitudinal follow-up study with 2,103 microbial samples, spanning a median duration of over 8.6 months and a median of 11 samples per woman. We devise a hierarchical Bayesian Markov model to estimate transition probabilities between CSTs, associations between the transitions and 16 relevant covariates, and individual variability among women.

93

94

Materials and Methods

Longitudinal clinical data

The samples originated from the PAPCLEAR monocentric longitudinal cohort study, which 95 followed 189 women longitudinally between 2016 and 2020. The participants were recruited 96 through posters and leaflets circulated at the main sexually transmitted infection detection 97 centre (CeGIDD) at the University Hospital of Montpellier (CHU) and at and around 98 university campuses in the city. The inclusion criteria were to be between 18 and 25 years 99 old, to be living in the area of Montpellier, France, to be in good health (no chronic disease), 100 not to have a history of human papillomavirus (HPV) infection (e.g., genital warts or high-101 grade cervical lesion), and to report at least one new sexual partner over the last 12 months. 102 Additional details about the protocol can be found elsewhere [17]. The longitudinal data 103

analysed in the present study are available at https://doi.org/10.57745/FHQR9Z.

The inclusion visit was performed by a gynaecologist or a midwife at the CeGIDD ¹⁰⁵ outside operating hours. After an interview, several samples were collected, including ¹⁰⁶ vaginal swabs with eSwabs (Coppan) in Amies preservation medium from which microbiota ¹⁰⁷ barcoding was later performed. The samples were aliquoted right after the visit and stored ¹⁰⁸ at -20°C, before being transferred to -70°C within a month. The participants also filled in ¹⁰⁹ a detailed questionnaire, which formed the basis of epidemiological covariates analysed in ¹¹⁰ 111

Subsequent on-site visits were scheduled every two or four months, depending on the 112 HPV status. In between on-site visits, women were asked to perform eight self-samples at 113 home with eSwabs in Amies medium and to keep them in their freezer. The self-samples 114 were brought back in an isotherm bag at the next visit. These were then stored with the 115 swab at -70°C until processing. 116

117

Microbiota metabarcoding and quantification

The microbiota metabarcoding was performed on 200μ L of vaginal swabs specimen stored ¹¹⁸ at -70° in Amies medium. The DNA extraction was performed using the MagAttract ¹¹⁹ PowerMicrobiome DNA/RNA kit (Qiagen). Next-generation sequencing of the V3-V4 ¹²⁰ region of the 16S gene [18] was performed on an Illumina HiSeq 4000 platform (150 base ¹²¹ pairs paired-end mode) at the Genomic Resource Center at the University of Maryland ¹²² School of Medicine. ¹²³

The taxonomic assignment was performed using the software package SpeciateIT (https: 124 //github.com/Ravel-Laboratory/speciateIT) and the CSTs were determined using the 125 VALENCIA software package [9]. To examine longitudinal patterns, the present study included participants who contributed at least three samples: 125 women met the inclusion 127 criterion, giving 2,103 samples in total.

Covariates

In the PAPCLEAR study, a questionnaire was given to each participant to record patientlevel meta-data. We initially considered the following covariates based on previously proposed roles in influencing the vaginal milieu:

129

- 1st menstr. Number of years since the first menstruation: The morphology of the human vagina changes throughout life and the onset of puberty marks a key event that triggers cascading changes [19].
 - Alcohol Average number of glasses of alcoholic drinks consumed per week: Chronic presence 136 of alcohol in the genital environment has been linked to a shift in the immune and 137 microbiological conditions [20].
 - Antibio. Application of antibiotics during the study, either systemic (Antibio. (Systemic)) 139
 or genital (Antibio. (Genital)): The bacterial composition responds rapidly and 140
 transiently to antibiotic treatments that target bacteria either broadly or with a 141
 narrow taxonomic scale [21].

BMI	Body mass index (BMI): Obesity has been implicated in elevating vaginal microbiota	143
	diversity and promoting $Prevotella$ associated with BV [22].	144
Caucasian	Identity as Caucasian ethnicity or other: Ethnicity has been linked to variation in	145
	vaginal microbiota compositions in several studies [6]. However, causal mechanisms	146
	remain an open question.	147
Cigarettes	Cigarette smoking: Smoking has been implicated in the development of BV due to its	148
	anti-estrogenic effects and the presence of harmful substances such as benzo[a]pyrene	149
	diol epoxide (BPDE) [23].	150
Horm. contra.	Use of hormonal contraception during the study: The vaginal hormonal landscape is	151
	affected by the use of hormonal contraceptives [24].	152
Lubricant	Use of lubricant during the study: Personal lubricants contain various chemicals that	153
	differentially impact the growth of vaginal microbes in-vitro [25].	154
Menstr. cup	Use of menstrual cups during the study: The vaginal microenvironment may be	155
	altered by the use of menstrual cups both physically and chemically. An elevated	156
	risk of fungal infections has been reported [26].	157
Partners	Cumulative number of sexual partners: The genital microbiome can be transferred	158
	between sexual partners [27]. Such an external input could destabilise the resident	159
	community.	160

- Red meat Average number of meals that include red meat consumption per week: Diet alters 161 the vaginal environment for microbes. An unhealthy diet, linked to a high proportion 162 of red meat consumption, has been linked to an elevated risk of BV [28]. 163
- Regular condom Regular use of condoms during sexual intercourse: Condom use can modify the vaginal microenvironment by altering the exchange of microbes between partners [29]. 165
 - Regular sport Engaging in regular sporting activities, over 50% of the time: Physical activities 166 influence immune responses, with leisure-time physical activity associated with a 167 reduced risk of suspected bacterial infections compared to sedentary behaviour [30]. 168
 - Stress Average stress level reported from 0 (min) to 3 (max): Stress hormones may disrupt 169 vaginal flora, for instance, by inhibiting glycogen production, which is the primary 170 fuel for lactobacilli [31].
 - Tampon Use of tampons during the study: The use of internal menstrual health products
 like tampons directly alters the vaginal environment, although negative effects from
 tampon use are seldom reported [32].
 - Vag. product Use of vaginal cream/tablet/capsule/gel/wipe during the study: Women frequently 175
 use over-the-counter vulvovaginal treatments that contain a variety of chemical components. However, the clinical effectiveness of these products in preventing BV is 177
 seldom systematically evaluated [33].

Chlamydia Tested positive for chlamydia.

Female/male affinity	Affinity to female/male partner: Genital microbiome transfers during sexual activity	180
	are anticipated to vary based on the genders of the partners [34].	181
Pregnancy	History of pregnancy: Pregnancy significantly changes the cervicovaginal environ-	182
	ment, with increased estrogen from the ovaries and placenta leading to higher vaginal	183
	glycogen. This supports the growth of <i>Lactobacillus</i> species [35].	184
Spermicide	Use of spermicide during the study: Spermicides are chemicals that prevent sperm	185
	from reaching an egg, but their use can change the vaginal microflora, potentially	186
	increasing the risk of genitourinary infections [36].	187
Vag. douching	Use of vaginal douching during study: Vaginal douching, the practice of washing in-	188
	side the vagina with a liquid solution, has been shown to increase the risk of disturbing	189

the natural balance of vaginal flora [37].

Out of the covariates initially considered above, we excluded six (Chlamydia, Female 191 affinity, Male affinity, Pregnancy, Spermicide and Vag. douching) as data were severely 192 skewed towards the most common value (> 90% of data). During the study, any use of 193 antibiotics was recorded with the date and we distinguished systemic (Antibio. (Systemic)) 194 and genital topical (Antibio. (Genital)) applications, corresponding to 'Gynecological anti-195 infectives and antiseptics' ('G01' ATC codes), which consisted of metronidazole treatments, 196 and 'Antibacterials for systemic use' ('J01' ATC codes), which were more diverse. Since 197 the exact dates of treatment were recorded, Antibio. (Systemic) and Antibio. (Genital) 198 were included as time-inhomogenous covariates in the model. All other covariates were 199

190

considered time-homogeneous meaning that the variation is among women, and static 200 through time because the precise timing of changes in the covariate values was unknown. 201

To facilitate the comparison of covariate effects, we centred and scaled continuous vari-202 ables [38] and deviation-coded binary variables. These transformations ensure that all 203 covariates are modelled in a comparable scale and the intercept is located at a "representa-204 tive reference value" of the modelled population: i.e., the population mean for continuous 205 and the theoretical mid-point for binary values. Four continuous covariates (i.e., Alcohol, 206 BMI, Partners, and Red meat) were log-transformed before scaling due to their right-207 skewed distribution. We found no strong correlations among the covariates included in the 208 analysis (Supplementary Information S1). 209

210

211

Modelling

Markov model

Markov models are statistical models used to represent systems that transition between ²¹² discrete states over time. These models are 'memoryless', meaning that the probability of ²¹³ transition to another state depends on the current state, but not its historical path. In ²¹⁴ clinical research, these models are often used to predict the transitions among health states ²¹⁵ (e.g., health, illness and remission), and the propensity to transition between these states is ²¹⁶ estimated from longitudinal follow-up data. Clinical follow-up data are typically modelled ²¹⁷ using the continuous-time Markov model [39], in which the probability of transition over ²¹⁸

a given interval depends on the instantaneous transition intensity and the amount of time 219 spent in the current state. 220

Vaginal microbiota state transitions are classically studied using continuous-time Markov²²¹ models [13–15, 40, 41]. Our application of the continuous-time Markov model differs from²²² those of the existing literature in its hierarchical Bayesian formulation, which allowed us²²³ to quantify individual variability among women (as unobserved heterogeneity, or random²²⁴ effects) and to estimate many covariate effects simultaneously (through the use of weakly²²⁵ informative priors).²²⁶

Transition intensities

Transition intensities, q, refer to the instantaneous rate of moving from state i to state j in a participant p (e.g., CST I to CST IV), a process that may be affected by a vector of covariates, X. Taking the form of a proportional hazards model, these rates can be expressed as:

$$q_{p,i,j} = \operatorname{Exp}(\mu_{p,i,j} + \beta_{i,j} X), \tag{1}$$

where $\mu_{p,i,j}$ is the intercept and $\beta_{i,j}$ is the coefficient expressing the impact of a covariate(s). This intercept is further defined by the equation,

$$\mu_{p,i,j} = (\hat{\mu}_{i,j} + s_{p,i,j}) \cdot \mu_{sd} + \bar{\mu}, \tag{2}$$

227

where $\bar{\mu}$ and μ_{sd} are the prior mean and standard deviation of the intercept such that $_{228}$ $\hat{\mu}_{i,j} \cdot \mu_{sd} + \bar{\mu}$ constitutes the non-centred parameterisation of the population-level intercept, $_{229}$ $\mu_{i,j}$ and is assumed to be normally distributed, i.e., $\hat{\mu}_{i,j} \sim \mathcal{N}(0,1)$. $_{230}$

Additionally, we allowed for unobserved heterogeneity in μ , i.e., $s_{p,i,j}$, where

$$s = \operatorname{diag}(sd_s) \cdot L_s \cdot z_s. \tag{3}$$

We sampled from the corresponding weakly informative priors, namely $sd_s \sim t_4(0,1)$, 231 $L_s \sim \text{LKJCorrCholesky}(2)$ (which slightly favours correlations among unobserved hetero-232 geneity closer to zero, reducing the likelihood of extreme positive or negative correlations), 233 and $z_s \sim \mathcal{N}(0,1)$, as recommended by the Stan development community [42, 43]. The 234 multivariate normal density and the LKJ prior require the matrix parameters to be de-235 composed, which can be computationally intensive if done repeatedly. To ensure compu-236 tational efficiency and numerical stability, the model was directly parameterised using the 237 Cholesky factors of correlation matrices. This approach uses a multivariate version of the 238 non-centred parameterisation. 239

For regression coefficients, the Student-t distributions with degrees of freedom 4 to 7 are ²⁴⁰ recommended as generic, weakly informative, priors [43]: we sampled β from $\beta \sim t_4(0,1)$, ²⁴¹ which places a comparatively wide tail within the recommendation. As all of our covariates ²⁴² have been proposed to impact vaginal microbiota communities *a priori* (see above), we did ²⁴³ not strongly regularise the priors, for example, through the use of horseshoe priors [44]. ²⁴⁴

We note that all covariates were modelled simultaneously, such that the interpretation of 245 each coefficient is conditional upon other covariates included and accounts for the influence 246 of other factors. We assumed that the covariates affect the transitions symmetrically (i.e., 247 $\beta_{j,i} = -\beta_{i,j}$), meaning that the influence of a covariate on the affinity (or aversion) towards 248 a particular CST is consistent, regardless of the direction of the transition. 249

Collectively, the transition intensities form the matrix, Q_p , in which the sum of intensities across a row, i.e., all transitions from a particular state, is defined to be zero, such that we have the following equation for the diagonal entries [39]:

$$q_{p,i,i} = -\sum_{j \neq i} q_{p,i,j}.$$
(4)

Transition probabilities and likelihood

Taking the matrix exponential of the Q_p matrix for each participant, p, we compute the matrix P_p such that:

$$P_p = \operatorname{Exp}((t_{k+1} - t_k) Q_p),$$
(5)

where k represents the sample identity for a given individual. The P_p matrix contains the transition probabilities between two observations (at k and k+1) and $t_{k+1}-t_k$ indicates the elapsed time between two observations.

Finally, the probability of observing a given state at the next sampling event (i.e., at

250

(k+1) is modelled by the categorical distribution:

$$y_{k+1} \sim \text{Categorical}(P_p[y_k,])$$
 (6)

256

where $P_p[y_k]$ is the y_k th row of the P_p matrix containing the probabilities of transition 254 from the state observed at k.

Model fitting

We used a Bayesian approach to fit the above continuous-time Markov model to longitudinal data of vaginal microbiota CSTs. In total, the model consisted of 57 parameters and 12 hyper-parameters. Our model was written in Stan 2.26.1 and fitted through the RStan interface 2.32.3 [45]. The Stan programme is available at https://doi.org/10.57745/FHQR9Z. 260

One participant lacked information on the years since their initial menstruation. We ²⁶¹ imputed missing values using the mice package [46] and generated 10 imputed datasets to ²⁶² be fitted separately. For each imputed dataset, we fitted the model in parallel using four ²⁶³ independent chains, each with 10,000 sampled iterations and 1,000 warm-up iterations. ²⁶⁴ The MCMC samples from separate runs (i.e., based on differently imputed data) were ²⁶⁵ subsequently combined for inference. ²⁶⁶

We confirmed over 1,000 effective samples per imputed dataset and ensured convergence of independent chains ($\hat{R} < 1.01$) for all parameters [47]. We carried out a posterior predictive check by comparing the observed and predicted CST frequency. We also quanti-

fied the posterior z-score and posterior contraction to examine the accuracy and precision 270 of posterior distributions and the relative strength of data to prior information [48] (Supplementary Information S2).

Counterfactual predictions

We took advantage of the parameterised model to simulate the population-level outcomes ²⁷⁴ of each covariate, assuming that all covariates, but a focal one, are at the representative ²⁷⁵ reference value (as described above) and then varying the focal parameter within the range ²⁷⁶ of values observed in the studied cohort. The model predictions were generated by ran-²⁷⁷ domly drawing 100 samples from the posterior distributions and simulating the Markov ²⁷⁸ model for each sampled parameter set. We focused on the CST frequency as the outcome ²⁷⁹ of interest. ²⁸⁰

Results and Discussion

CSTs in the cohort

As is typical of vaginal microbiota communities, the microbial compositions sampled in ²⁸³ PAPCLEAR were highly structured, and characterised by a relatively small number of ²⁸⁴ operational taxonomic units (OTUs). The dominant species within these communities ²⁸⁵ aligned closely with specific community state types (CSTs) as defined by Ravel et al. [6]. ²⁸⁶ For example, CST I was primarily associated with *L. crispatus* and CST III with *L. iners.* ²⁸⁷

273

281

282



Figure 1: Vaginal community state types (CSTs), diversity (Shannon Index), and relative coverage of the 15 most common taxonomic operational units (OTU) of 2,103 samples from the PAPCEAR cohort. In over 98.5% of samples, a single of these 15 OTUs represented the most common OTU.

In contrast, and as expected, CST IV communities exhibited a higher degree of microbial ²⁸⁸ diversity compared to CSTs dominated by lactobacilli, reflecting a broader range of species ²⁸⁹ typical of this community type (Fig. 1). ²⁹⁰

Our longitudinal dataset from the PAPCLEAR cohort represents one of the largest ²⁹¹ analysed to date in the context of the vaginal microbiota. Detailed participant characteristics are presented in Table 1. Briefly, the participants were between 18 and 25 years old ²⁹³ and the majority of the 2,103 samples (73.7%) were self-collected at home, the rest being ²⁹⁴ collected during on-site visits (Fig. 2a). The median follow-up duration was 8.64 months ²⁹⁵ and the most common intervals between analysed samples were seven and 28 days (Fig. 2a ²⁹⁶ & b). On average, each of the 125 participants contributed 11 samples (Fig. 2c). ²⁹⁷

The metabarcoding analysis on 16S RNA with the VALENCIA algorithm [9] was used 298 to assign each sample to a CST. The vaginal microbiota communities were variable across 299 women and over time (Fig. 2d). As CSTs I, II, and V are all dominated by lactobacilli 300 and considered 'optimal' in terms of health, yet the latter two are rare ($\sim 4\%$ of all sam-301 ples combined), we pooled the three optimal communities for further investigation. Over-302 all, optimal communities were the most frequent, representing 44.5% of samples, followed 303 by 'sub-optimal' (CST III) at 35.2% and 'non-optimal' communities (CST IV) at 20.4%304 (Fig. 2e and Table 1). 305



Figure 2: Summary of vaginal microbiota samples analysed in the PAPCLEAR study. a) Intervals between sampling events for clinical (i.e., on-site) and home samples. b) Follow-up duration per participant. c) Number of samples analysed per participant. d) Vaginal microbiota Community State Types (CST) over time in 125 participants. For visualisation, data are truncated at 750 days for a single individual whose duration exceeds this threshold. e) Frequency of the optimal (i.e., CSTs I, II, and V combined), sub-optimal (CST III) and non-optimal (CST IV) communities in all samples.

Probabilities of CST persistence

We implemented a continuous-time Markov model to capture the CST dynamics. Simulations based on the estimated parameters of our model (i.e., posterior predictive check) confirmed that it accurately captures the observed CST prevalence (Fig. 3a). The optimal, 309

Table 1: Summary profile of vaginal microbiota samples and covariates in the PAPCLEAR study. Q1 and Q3 refer to first (25%) and third (75%) quantiles. Level = 1 indicates the presence of a binary condition. See Materials and Methods for the covariate definitions.

	Level	Summary
Samples (Participants)		2103~(125)
CST (%)	Ι	847 (40.3)
	II	39(1.85)
	III	740(35.2)
	IV-A	54(2.57)
	IV-B	342(16.3)
	IV-C	32(1.52)
	V	49(2.33)
Sample type $(\%)$	On-site	553 (26.3)
	Home	1550(73.7)
Sampling interval (median $(Q1,Q3)$)		$21 \ (7, \ 28)$
Follow-up duration (median $(Q1,Q3)$)		8.64 (5.36, 14.0)
Samples per subject (median (Q1,Q3))		11(7, 16)
Covariates		
Identifying as 'Caucasian' (%)	1	102 (81.6)
BMI (median $(Q1,Q3)$)		21.19(19.78, 23.46)
Alcohol (median $(Q1,Q3)$)		3.14(1.40, 5.07)
Smoker $(\%)$	1	36(28.8)
Stress level (from 0 to 3, median $(Q1,Q3)$)		$1.41 \ (1.00, \ 1.75)$
Regular sport practice $(\%)$	1	61 (48.8)
Red meat consumption (times per week, median $(Q1,Q3)$)		$0.50 \ (0.16, \ 1.00)$
Years since 1st menstruation (median $(Q1,Q3)$)		9(7, 10)
Hormonal contraception $(\%)$	1	32(25.6)
Menstrual cup user $(\%)$	1	46(36.8)
Vaginal product user $(\%)$	1	73(58.4)
Tampon user (%)	1	89(71.2)
Lifetime number of partners (median $(Q1,Q3)$)		5(3, 11)
Lubricant use $(\%)$	1	58(46.4)
Regular condom use by partner $(\%)$	1	23(18.4)
Male affinity (%)	1	124 (99.2)
Chlamydia infection at inclusion $(\%)$	1	7(5.6)
Pregnancy during follow-up (%)	1	4(3.2)
Vaginal douching (%)	1	4(3.2)
Spermicide user $(\%)$	1	1(0.8)
Female affinity (%)	1	10(8.0)
Systemic antibiotic treatment $(\%)$	1	65 (52.0)
Genital antibiotic treatment (%)	1	30(24.0)



Figure 3: **Prevalence and transition probabilities among vaginal microbiota community state types (CSTs).** a) Observed (bars) and predicted prevalence (crosses) of CSTs I (II, V), III and IV. The model predictions were generated by drawing 100 random samples from the posterior distributions and simulating the Markov model for each sampled parameter set. b) Mean estimated weekly transition probabilities of CSTs I (II, V), III and IV. The arrow thickness indicates the persistence or transition probability.

CST I (II, V), and sub-optimal, CST III, communities showed a high degree of stability, 310 with weekly probabilities to remain in the current state estimated at 87% (95% credibility 311 interval (95CrI): 78 - 93%) and 81% (95CrI: 68 - 90%), respectively (Fig. 3b). In contrast, 312 the weekly persistence probability of the non-optimal CST IV was 60% (95CrI: 35 - 80%, 313 Fig. 3b). These transition probabilities translate into sojourn times (i.e., the expected time 314 spent in a given state before moving to another) in CST I (II, V), III and IV of 6.9 days 315 (95CrI: 2.9 - 13.6 days), 4.23 days (95CrI: 1.8 - 8.4 days) and 1.6 days (95CrI: 0.58 - 3.8 316 days), respectively. 317

The reported persistence and transition probabilities in the literature vary widely based ³¹⁸ on the cohort characteristics. For example, focusing on women during pregnancy, DiGiulio ³¹⁹ et al. [13] estimated that the four *Lactobacillus*-dominated CSTs (CSTs I, II, III, and ³²⁰ V) were more stable than CST IV. Notably, both CST I and II showed 98% probability ³²¹ of weekly persistence. The enhanced persistence of *Lactobacillus*-dominated communities ³²² during pregnancy owes itself to specific vaginal conditions during pregnancy including the ³²³ up-regulation of oestrogen and progesterone that facilitates lactobacilli [13, 49].

In addition, the temporal dynamics of vaginal microbiota are notably different in women³²⁵ with BV. In contrast to pregnant women, those experiencing symptomatic BV generally³²⁶ exhibit less stable vaginal microbiota communities. In the cohort of Ravel et al. [50], ³²⁷ which focused on women with symptomatic BV, Brooks et al. [40] found significantly lower³²⁸ stability across all CSTs. The probability of these CSTs persisting ranged from 38% to³²⁹ 48%, with CST I persisting only 46% of the time over a week.³³⁰

Among studies that focused on non-pregnant, healthy young women — with no partic-331 ular emphasis on BV — the analysis by Brooks et al. [40] of the Chaban et al. cohort [16] 332 (N = 27; Canada) estimated weekly persistence probabilities of 75% for CST I, 78% for III, 333 60% for IV-A, and 88% for V. In the Gajer et al. dataset [12] (N = 32; USA), analysed again 334 by Brooks et al., [40], CST I, II and III demonstrated 72%, 84% and 77% weekly persis-335 tence probabilities, respectively. In this dataset, CST IV sub-categories showed markedly 336 different stability with CST IV-A with weekly persistence of 38% and CST IV-B with 337 persistence of 82%. A third study, Munoz et al. [15] (N = 88; South Africa), reported 338

the stability of vaginal microbiota in women in a three-month time frame using a differ-339 ent microbiota classification system consisting of four categories predominantly associated 340 with: L. crispatus (similar to CST I), L. iners (similar to CST III), G. vaginalis (similar 341 to CST IV), or *Prevotella* spp. (similar to CST IV). They found similar persistence for 342 CST I and CST IV-like communities ranging from 51 to 53% over three months while the 343 CST III-like community was more stable at 62% over the same period. Recasting in the 344 three-month time scale, our estimates show the same extent of stability for CST I(II, V) at 345 51% (95% CrI: 29-72%) while CST III (38%, 95% CrI: 19-61%) and CST IV (15%, 95% CrI: 346 5-34%) were less stable. Taken together, our estimates of vaginal microbiota community 347 stability are within the range of values reported in other cohorts. However, the dynamics 348 of vaginal microbiota communities are likely geographically variable even among healthy 349 young women. 350

Covariate effects on transitions

The Bayesian approach, which can accommodate vaguely informative priors on the covariate effects, allows for the simultaneous inclusion of many covariates (as hazard ratios; Eq. 1) which would otherwise prove difficult in Markov models [39]. We identified 16 covariates based on previously proposed roles in influencing the vaginal milieu and assumed that covariates have a symmetrical effect on CST transitions: e.g., the magnitude of a given covariate effect on the transition from CST I to III is identical to that on the transition from CST III to I. We identified alcohol consumption as the strongest and most consistent

351

effect while several other covariates were identified as possible drivers of CST transitions. ³⁵⁹

360

Alcohol consumption

The estimated hazard ratios on community transitions indicate that alcohol consumption ³⁶¹ favoured the sub-optimal (CST III) community over optimal (CST I(II, V)) with 97% ³⁶² probability (Fig. 4). Because of our symmetry assumption, this can mean that alcohol ³⁶³ consumption increases the pace of transition from CST I(II, V) to CST III or reduces that ³⁶⁴ in the opposite direction by the same magnitude. Alcohol consumption also tended to ³⁶⁵ favour CST IV over CST III, although with a lower credibility level (with 73% probability ³⁶⁶ of the hazard ratio \neq 1, Fig. 4).

To examine how these effects translate to the population level, we carried out counter-368 factual simulations in which all participant characteristics were set to the representative 369 value observed in the studied cohort, except for alcohol consumption, which ranged from 370 non-drinking to the level of the heaviest drinking observed in our cohort (19 drinks per 371 week). The simulations demonstrated that the expected prevalence of the optimal (CST I 372 (II, V)) community was 18% (95% CrI of 9 to 27%) higher in a hypothetical population 373 of non-drinkers compared to that of average-level drinkers who consumed three drinks per 374 week (Fig. 5; Supplementary Information S3). In turn, the prevalence of the optimal com-375 munity was 19% (95% CrI of 10 to 29%) higher in the population of average-level drinkers 376 than in the heaviest drinkers. As the optimal community declined with alcohol consump-377 tion, the prevalence of the non-optimal (CST IV) community was found to be 9% (95% CrI 378



Figure 4: Estimated covariate effects on community transition rates. With the symmetry assumption, there are three sets of covariate effects on transitions. The impact of covariates on community transition rates was estimated for a given set of community states as the log hazard ratio, β . The figure shows the posterior distributions of $\exp(\beta)$, the hazard ratio for the three sets of transition sets, and the corresponding 16 covariates. The numbers on the right-hand side of each panel indicate the probability that the estimated effect is different from the hazard ratio of 1 (i.e., the proportion of posterior distributions sampled on the dominant side of the effect). For example, alcohol consumption was estimated to favour CST III over CST I (II,V) at a credibility level of 97%.

of 2 to 15%) higher among average drinkers compared to non-drinkers. Therefore, while the strongest impact of alcohol on community transitions appears to be between the optimal (CST I (II, V)) and sub-optimal (CST III) communities, an additional, non-zero impact on the sub-optimal to non-optimal (CST IV) transition means that alcohol consumption ultimately promotes non-optimal communities at the expense of optimal ones. As the effects of covariates are estimated simultaneously, potential confounding factors, including the number of partners, condom use and smoking, are controlled for in our findings.

Alcohol consumption may impact the vaginal microbiota through a variety of mecha-



Figure 5: Counter-factual simulations predict population-level consequences of covariates. Based on estimated hazard ratios (Fig. 4), the population-level impact (i.e., the prevalence of CST I (II,V), III and IV) was simulated for each covariate. The vertical dashed lines indicate the intercept used in estimation: i.e., the population mean for continuous and midpoint for binary variables. For continuous variables, the range of values explored was determined by the minimum and maximum values reported in the PAP-CLEAR study.

nisms. Physiologically, the chronic presence of alcohol in the genital environment has been ³⁸⁷ linked to a shift in immune and microbiological conditions [20]. In addition, alcohol is a ³⁸⁸

known modifier of sexual behaviour, which in turn has been demonstrated to increase the ³³⁹ risk of BV, linked to CST IV [51]. Finally, alcohol alters the microbial profile in other ³⁹⁰ body parts, which in turn could cross over to the vaginal milieu. For example, *Prevotella*, ³⁹¹ a genus commonly found in CST IV communities, is enriched in the oral microbiota of ³⁹² drinkers [52]. Similarly, others postulate the effect of alcohol on the gut microbiota may ³⁹³ have a concurrent influence on the vaginal microbiota [53]. ³⁹⁴

While there remains a lack of consensus among existing studies (briefly reviewed by 395 Froehle et al. [53]), cohort and cross-sectional studies from diverse geographical contexts 396 (namely, Australia, Denmark, Sweden, Thailand, Tanzania, Uganda and USA) have pre-397 viously reported an association between alcohol consumption and BV [53–61]. In addition 398 to corroborating these findings, our Markov model offers a novel insight into the ecology of 399 microbial communities underlying these observations: alcohol consumption destabilises the 400 optimal (CST I (II, V)) communities towards sub-optimal (CST III), which opens the gate 401 for the deterioration towards non-optimal (CST IV), associated with BV. To the authors' 402 knowledge, there have been no alcohol cessation studies reporting its impact on vaginal 403 microbiota. Such studies are necessary to establish causal links, similar to those conducted 404 on the effects of smoking [23], douching [62], and antibiotics [21] on vaginal microbiota 405 compositions. 406

Potential effects of other covariates

Other factors with possible effects on transitions (i.e., with more than 80% probability of $_{408}$ hazard ratio $\neq 1$) included the use of vaginal intimate hygiene products, number of sexual $_{409}$ partners and self-reported 'Caucasian' identity. $_{410}$

407

Vaginal hygiene products: The use of vaginal hygiene products, defined broadly 411 here to include vaginal cream, tablet, capsule, gel and wipe, appeared to have multifaceted 412 effects. Between CST I (II, V) and CST III, their use was positively linked to maintaining 413 or transitioning to CST I (II, V) with 90% probability (Fig. 4). For the CST I (II, V) and 414 CST IV pair, it tended to favour a shift towards CST IV, with 85% probability. Finally, 415 between CST III and CST IV, their use was more likely to support the persistence or a 416 shift towards CST III, also with 90% probability. The circular effects suggest that women 417 may experience different effects of the products marketed for 'vaginal intimate hygiene' 418 depending on the predisposition with certain CSTs. Nonetheless, the circular effects on 419 community transitions meant that there was no noticeable impact at the population level 420 in our counterfactual simulations (Fig. 5). 421

Number of sexual partners: A higher number of sexual partners was also found ⁴²² to potentially favour CST IV over CST III, increasing the risk of maintaining (or transitioning to) CST IV with 89% probability of the hazard ratio $\neq 1$. The association between ⁴²⁴ CST IV and the lifetime number of partners is consistent with the hypothesis that external ⁴²⁵ importation of microbes could alter the dynamics of vaginal microbiota and is in line with ⁴²⁶

earlier work [63, 64]. Population-level simulations predict that an increasing number of 427 sexual partners tends to reduce the prevalence of the sub-optimal (CST III) community. 428 For example, CST III was 13% (95% CrI of 2 to 21%) less common in a hypothetical pop-429 ulation with the highest number of partners than one conforming to the average number. 430 The decrease was accompanied by a tendency for the other CSTs to increase, although the 431 trend was less clear for CST I(II,V) and CST IV, individually (Fig. 5).

Causasian identity: It is worth noting that our cohort was not designed to achieve 433 comprehensive coverage of self-reported ethnic identity, with over 80% identifying as Cau-434 casians (Table 1). Nonetheless, identifying oneself as a 'Caucasian' tended to favour CST III 435 over CST I(II, V) with 86% probability. European studies focusing on the role of ethnicity 436 are rare. However, a North American study has observed a qualitatively opposite trend: 437 CST III communities are comparably rare in women who identify themselves as Caucasian 438 compared to those identifying as Asian, Black and Hispanic (26.8 versus 42.7, 31.4 and 439 36.1%, respectively [6]). While previous studies have revealed differences in vaginal mi-440 crobiota compositions among ethnic groups, the relative importance of biological, societal, 441 and environmental factors remains an open question [6,65–67]. 442

Antibiotics: Notably, we found little association between antibiotic consumption and 443 CST transitions, neither for local treatment for BV (genital application of metronidazole) 444 nor systemic treatment (antibiotic treatment via oral intake). Such a lack of effect in 445 our study may be because the changes in the vaginal microbiota compositions following an 446 antibiotic treatment take place in a shorter time scale than our sampling intervals: the most 447

common sampling intervals were either 7 or 28 days (Table 1). In comparison, Brooks et 448 al. [40] found rapid CST transition following BV medication in the cohort of Ravel et al. [50], 449 which involved daily sampling. On a longer time scale, the re-emergence of BV-associated 450 communities following treatments is a well-documented clinical challenge [68–70]. 451

Unobserved individual variability in community transition

While we incorporated 16 covariates into our Markov model, some variations among women 453 remain unaccounted for. To quantify these, we estimated the extent of individual variability (i.e., unobserved heterogeneity, or random effects) in community transitions for each 455 transition pair using a hierarchical Bayesian approach (Eq.2 & 3). 456

452

The highest variability was observed among women in the transitions involving 'recov-457 ery' to an optimal (CST I (II,V)) from a non-optimal (CST IV) state (Fig. 6). On the 458 other hand, inverse transitions from optimal to non-optimal exhibited some of the lowest 459 individual variability. The same is true, although to a lesser extent, for the shifts from 460 sub-optimal (CST III) to optimal. These findings suggest that there are relatively lim-461 ited pathways leading to the deterioration of vaginal microbiota communities, whereas the 462 routes to recovery can be more individualised and the source of this variation remains to 463 be fully elucidated. 464

The presence of individual-level random effects indicates that a considerable part of the variability remains unaccounted for by the 16 covariates in this study. One possible cause is that our study left out key drivers of the vaginal milieu. For example, while menstrual cycles 467



Figure 6: Individual-level variability in vaginal microbiota community state type (CST) transitions. a) The population average (thick black) and individual (thinner colours) weekly transition probabilities. Between-women individual variation for transitions to b) a more optimal and c) a less optimal state. Colours indicate the type of transition between CSTs.

have been demonstrated to influence daily and weekly transitions [12], they were omitted 468 from our analysis because the timing of menstruation was ambiguous in the PAPCLEAR 469 study. Furthermore, while large-scale longitudinal studies present logistical challenges, a 470 citizen-science-based approach offers the potential for expanding the cohort size, thereby 471 enhancing the statistical power needed to examine additional covariates [71]. Secondly, 472 further resolution on individual variability may be gained by incorporating time-varying 473 covariates, which could accommodate changes in participant behaviours during the follow-474 up. In continuous-time Markov models, time-varying covariates are assumed piecewise 475

constant, meaning they are constant between sampling events [39]. Such an assumption is 476 convenient as covariate values are rarely known between sampling events. Without precise 477 knowledge of the timing of the covariate changes, however, it is unclear whether the previous 478 covariate value (at t-1) or the new covariate value (at t) should influence the transition. 479 Consequently, our analysis focused on static covariates, with the exception of antibiotic 480 treatments for which the exact application dates were known. Aggregating participant 481 behaviours as static covariates eliminated the uncertainty of covariate dynamics, albeit at 482 a potentially lost opportunity for further precision. 483

Limitations and opportunities

A potential limitation from a clinical methodological perspective is that the majority of samples were collected at home during the PAPCLEAR study. While home sampling could introduce variability, the participants were provided with detailed instructions to minimise the difference in swabbing techniques between on-site and home samples, and we verified consistency in sampling dates by having participants fill out online questionnaires during sampling.

484

Another possible limitation of our study is the resolution of microbiota community ⁴⁹¹ classification. We focused on three CST groups with varying health implications: optimal ⁴⁹² (CST I (II,V)), sub-optimal (III), and non-optimal (IV). This decision stemmed from the ⁴⁹³ fact that detailed classifications in a Markov model would increase the number of possible ⁴⁹⁴ transitions, and it would be difficult to estimate transitions between rare types. However, ⁴⁹⁵

significant functional differences may exist within these CSTs. For instance, the VALEN-CIA algorithm classifies subcategories within some CSTs [9], and Brooks et al. demon-407 strated that CST IV-B is more stable than CST IV-A [40]. We also note that there are 498 several clustering algorithms of microbial communities besides the CST framework [71,72], 499 which may offer differing insights on community transitions. Furthermore, the centroid 500 distance computed by VALENCIA for CST assignment may also be leveraged to develop a 501 quantitative, multi-dimensional perspective of the vaginal microbiota communities. Such 502 a quantitive perspective may enhance our understanding of within-CST variabilities — al-503 though we are unaware of an existing approach that accommodates the temporal patterns 504 in such data. Finally, the metagenomics approach holds the promise to uncover within-505 species diversities: e.g., metagenomics CSTs (MgCSTs) have identified with 25 distinct 506 communities [73]. Such an approach helps to identify lineage replacements in women with 507 stable CSTs and investigating the impact of antibiotic treatments on the prevalence of 508 resistance genes could yield insights into the within-species dynamics of vaginal microbes. 509

A promising direction for future research is the joint analysis of CST dynamics and ⁵¹⁰ sexually transmitted infections such as HPV. Previous studies have found a weak association between CST IV and HPV detection risk [74]. However, these studies tested the ⁵¹² CST effect after estimating transition rates and pooled all high-risk and low-risk HPVs, ⁵¹³ making it difficult to identify coinfections or reinfections. The PAPCLEAR cohort, with ⁵¹⁴ genotype-specific follow-ups, could provide new insights into the link between CST and ⁵¹⁵ HPV infection, potentially identifying causal relationships. ⁵¹⁶

Conclusion

We showcased a novel application of a hierarchical Bayesian Markov model to original ⁵¹⁸ clinical cohort data of vaginal microbiota dynamics. Our approach facilitated the simultaneous estimation of several covariate effects on community transitions and the identification ⁵²⁰ of unobserved variability in these transitions. Our work paves the way for an improved ⁵²¹ ecological understanding of microbial dynamics within the vaginal environment and indicates lifestyle alterations (such as reduced alcohol consumption) that may promote vaginal ⁵²² ⁵²³

Ethics

525

517

This study has been approved by the Comité de Protection des Personnes (CPP) Sud 526 Méditerranée I (reference number 2016-A00712-49); by the Comité Consultatif sur le Traitement de l'Information en matière de Recherche dans le domaine de la Santé (reference 528 number 16.504); by the Commission Nationale Informatique et Libertés (reference number MMS/ABD/ AR1612278, decision number DR-2016–488), by the Agence Nationale 530 de Sécurité du Médicament et des Produits de Santé (reference 20160072000007), and is 531 registered at ClinicalTrials.gov under the ID NCT02946346. 532

Funding

This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 648963, to SA). The authors acknowledge further support from the Fondation pour la Recherche Medicale (to TK), the Agence Nationale de la Recherche contre le SIDA (ANRS-MIE, to NT), and the MemoLife Labex (to BE).

Acknowledgements

The authors thank Olivier Supplisson for his helpful feedback. We acknowledge the ISO 540 9001 certified IRD i-Trop HPC (member of the South Green Platform) at IRD Montpel-1 lier for providing HPC resources that have contributed to the research results reported 542 within this article (bioinfo.ird.fr and www.southgreen.fr). DNA extracts were (partly) per-543 formed through the genotyping and sequencing facilities of ISEM (Institut des Sciences de 544 l'Evolution-Montpellier) and Labex Centre Méditerranéen Environnement Biodiversité. 545

References

 van de Wijgert JHHM. The vaginal microbiome and sexually transmitted infections are interlinked: Consequences for treatment and prevention. PLOS Medicine. 548 2017;14(12):e1002478.

539

546

- Haahr T, Zacho J, Bräuner M, Shathmigha K, Skov Jensen J, Humaidan P. Reproductive outcome of patients undergoing in vitro fertilisation treatment and diagnosed with bacterial vaginosis or abnormal vaginal microbiota: a systematic PRISMA review and meta-analysis. BJOG. 2019;126(2):200–207.
- Bilardi JE, Walker S, Temple-Smith M, McNair R, Mooney-Somers J, Bellhouse C, 554
 et al. The burden of bacterial vaginosis: women's experience of the physical, emotional, 555
 sexual and social impact of living with recurrent bacterial vaginosis. PLOS ONE. 556
 2013;8(9):e74378. 557
- [4] France M, Alizadeh M, Brown S, Ma B, Ravel J. Towards a deeper understanding of the vaginal microbiota. Nature Microbiology. 2022;7(3):367–378.
- [5] Cheng M, Ning K. Stereotypes about enterotype: the old and new ideas. Genomics, 560
 Proteomics and Bioinformatics. 2019;17(1):4–12. 561
- [6] Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, et al. Vaginal 562
 microbiome of reproductive-age women. Proceedings of the National Academy of 563
 Sciences. 2011;108:4680–4687. 564
- [7] France MT, Fu L, Rutt L, Yang H, Humphrys MS, Narina S, et al. Insight into the soft ecology of vaginal bacteria through integrative analyses of metagenomic and meta-transcriptomic data. Genome Biology. 2022;23(1):66.

- [8] Coudray MS, Madhivanan P. Bacterial vaginosis—A brief synopsis of the literature. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2020
 Feb;245:143–148.
- [9] France MT, Ma B, Gajer P, Brown S, Humphrys MS, Holm JB, et al. VALENCIA: 571
 a nearest centroid classification method for vaginal microbial communities based on 572
 composition. Microbiome. 2020;8(1):166. 573
- [10] Petrova MI, Reid G, Vaneechoutte M, Lebeer S. Lactobacillus iners: Friend or Foe? 574
 Trends in Microbiology. 2017;25(3):182–191. 575
- [11] Cancelo-Hidalgo MJ, Coello LB. Genitourinary syndrome of the menopause: vaginal 576
 health and microbiota. In: Cano A, editor. Menopause: a comprehensive approach. 577
 Cham; 2017. p. 91–107. 578
- [12] Gajer P, Brotman RM, Bai G, Sakamoto J, Schütte UM, Zhong X, et al. Temporal dynamics of the human vaginal microbiota. Science Translational Medicine. 580 2012;4(132):132ra52–132ra52.
- [13] DiGiulio DB, Callahan BJ, McMurdie PJ, Costello EK, Lyell DJ, Robaczewska A, 582
 et al. Temporal and spatial variation of the human microbiota during pregnancy. 583
 Proceedings of the National Academy of Sciences. 2015;112(35):11060–11065. 584

- [14] Serrano MG, Parikh HI, Brooks JP, Edwards DJ, Arodz TJ, Edupuganti L, et al. 585
 Racioethnic diversity in the dynamics of the vaginal microbiome during pregnancy. 586
 Nature Medicine. 2019;25(6):1001–1011. 587
- [15] Munoz A, Hayward MR, Bloom SM, Rocafort M, Ngcapu S, Mafunda NA, et al. 588
 Modeling the temporal dynamics of cervicovaginal microbiota identifies targets that 589
 may promote reproductive health. Microbiome. 2021;9(1):1–12. 590
- [16] Chaban B, Links MG, Jayaprakash TP, Wagner EC, Bourque DK, Lohn Z, et al.
 ⁵⁹¹ Characterization of the vaginal microbiota of healthy Canadian women through the
 ⁵⁹² menstrual cycle. Microbiome. 2014;2:1–12.
- [17] Murall CL, Rahmoun M, Selinger C, Baldellou M, Bernat C, Bonneau M, et al. 594
 Natural history, dynamics, and ecology of human papillomaviruses in genital in fections of young women: protocol of the PAPCLEAR cohort study. BMJ Open. 596
 2019;9(6):e025129. 597
- [18] Frank JA, Reich CI, Sharma S, Weisbaum JS, Wilson BA, Olsen GJ. Critical eval uation of two primers commonly used for amplification of bacterial 16S rRNA genes.
 Applied and Environmental Microbiology. 2008;74(8):2461.
- [19] Farage M, Maibach H. Lifetime changes in the vulva and vagina. Archives of Gynecology and Obstetrics. 2006;273:195–202.

- [20] Loganantharaj N, Nichols WA, Bagby GJ, Volaufova J, Dufour J, Martin DH, et al. 603
 The effects of chronic binge alcohol on the genital microenvironment of simian im munodeficiency virus-infected female rhesus macaques. AIDS Research and Human 605
 Retroviruses. 2014;30(8):783–791. 606
- [21] Mayer BT, Srinivasan S, Fiedler TL, Marrazzo JM, Fredricks DN, Schiffer JT. Rapid 607
 and profound shifts in the vaginal microbiota following antibiotic treatment for bacterial vaginosis. Journal of Infectious Diseases. 2015;212(5):793–802.
- [22] Si J, You HJ, Yu J, Sung J, Ko G. *Prevotella* as a hub for vaginal microbiota under 610
 the influence of host genetics and their association with obesity. Cell Host & Microbe. 611
 2017;21(1):97–105. 612
- [23] Brotman RM, He X, Gajer P, Fadrosh D, Sharma E, Mongodin EF, et al. Association
 between cigarette smoking and the vaginal microbiota: a pilot study. BMC Infectious
 Diseases. 2014;14(1):1–11.
- [24] Achilles SL, Austin MN, Meyn LA, Mhlanga F, Chirenje ZM, Hillier SL. Impact of 616
 contraceptive initiation on vaginal microbiota. American Journal of Obstetrics and 617
 Gynecology. 2018;218(6):622–e1. 618
- [25] Laniewski P, Owen KA, Khnanisho M, Brotman RM, Herbst-Kralovetz MM. Clinical and personal lubricants impact the growth of vaginal lactobacillus species and colo-620

> nization of vaginal epithelial cells: an in vitro study. Sexually Transmitted Diseases. 621 2021;48(1):63–70. 622

- [26] Tessandier N, Uysal IB, Elie B, Selinger C, Bernat C, Boué V, et al. Does exposure to different menstrual products affect the vaginal environment? Molecular Ecology. 624 2023;32(10):2592–2601.
- [27] Vodstrcil LA, Twin J, Garland SM, Fairley CK, Hocking JS, Law MG, et al. The 626
 influence of sexual activity on the vaginal microbiota and *Gardnerella vaginalis* clade 627
 diversity in young women. PLOS ONE. 2017;12(2):e0171856.
- [28] Noormohammadi M, Eslamian G, Kazemi SN, Rashidkhani B. Association between 629
 dietary patterns and bacterial vaginosis: a case-control study. Scientific Reports. 630
 2022;12(1):12199. 631
- [29] Hutchinson KB, Kip KE, Ness RB. Condom use and its association with bacterial vaginosis and bacterial vaginosis-associated vaginal microflora. Epidemiology. 2007;p. 633
 702–708.
- [30] Pape K, Ryttergaard L, Rotevatn TA, Nielsen BJ, Torp-Pedersen C, Overgaard C, 635
 et al. Leisure-time physical activity and the risk of suspected bacterial infections. 636
 Medicine and Science in Sports and Exercise. 2016;48(9):1737–1744. 637
- [31] Amabebe E, Anumba DO. Psychosocial stress, cortisol levels, and maintenance of vaginal health. Frontiers in Endocrinology. 2018;p. 568.

- [32] Klebanoff MA, Nansel TR, Brotman RM, Zhang J, Yu KF, Schwebke JR, et al. 640
 Personal hygienic behaviors and bacterial vaginosis. Sexually Transmitted Diseases. 641
 2010;37(2):94.
- [33] Van Kessel K, Assefi N, Marrazzo J, Eckert L. Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: a systematic review.
 644 Obstetrical & Gynecological Survey. 2003;58(5):351–358.
- [34] Ma ZS. Microbiome transmission during sexual intercourse appears stochastic and supports the red queen hypothesis. Frontiers in Microbiology. 2022;12:789983.
- [35] Juliana NC, Peters RP, Al-Nasiry S, Budding AE, Morré SA, Ambrosino E. Composi tion of the vaginal microbiota during pregnancy in women living in sub-Saharan Africa:
 a PRISMA-compliant review. BMC Pregnancy and Childbirth. 2021;21(1):1–15.
- [36] Gupta K, Hillier SL, Hooton TM, Roberts PL, Stamm WE. Effects of contraceptive ⁶⁵¹
 method on the vaginal microbial flora: a prospective evaluation. Journal of Infectious ⁶⁵²
 Diseases. 2000;181(2):595–601. ⁶⁵³
- [37] Brotman RM, Klebanoff MA, Nansel TR, Andrews WW, Schwebke JR, Zhang J,
 et al. A longitudinal study of vaginal douching and bacterial vaginosis—a marginal
 structural modeling analysis. American Journal of Epidemiology. 2008;168(2):188–196.
- [38] Gelman A. Scaling regression inputs by dividing by two standard deviations. Statistics 657
 in Medicine. 2008;27(15):2865–2873.

[39]	Christopher H Jackson. Multi-State Models for Panel Data: The msm Package for R.	659
	Journal of Statistical Software. 2011;38(8):1–29.	660
[40]	Brooks JP, Buck GA, Chen G, Diao L, Edwards DJ, Fettweis JM, et al. Changes	661
	in vaginal community state types reflect major shifts in the microbiome. Microbial	662
	Ecology in Health and Disease. $2017;28(1):1303265.$	663
[41]	Fettweis JM, Serrano MG, Brooks JP, Edwards DJ, Girerd PH, Parikh HI, et al. The	664
	vaginal microbiome and preterm birth. Nature Medicine. 2019;25(6):1012–1021.	665
[42]	Team SD. Stan Functions Reference; 2024. Accessed: 2024-02-05. https://mc-stan.	666
	org/docs/functions-reference.	667
[43]	Stan Development Team. Prior Choice Recommendations; 2023. Accessed: 2024-02-	668
	15. https://github.com/stan-dev/stan/wiki/Prior-Choice-Recommendations.	669
[44]	Piironen J, Vehtari A. Sparsity information and regularization in the horseshoe and	670
	other shrinkage priors. Electronic Journal of Statistics. 2017;11(2):5018–5051.	671
[45]	Stan Development Team. RStan: the R interface to Stan; 2023. R package version	672
	2.32.3. Available from: https://mc-stan.org/.	673
[46]	van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained	674
	equations in R. Journal of Statistical Software. 2011;45(3):1–67.	675

- [47] Stan Development Team. The Stan Core Library; 2018. Version 2.18.0. Available 676
 from: http://mc-stan.org/17.
- [48] Betancourt M. Towards a principled Bayesian workflow; 2020. Available from: https://betanalpha.github.io/assets/case_studies/principled_ bayesian_workflow.html.
- [49] Odogwu NM, Onebunne CA, Chen J, Ayeni FA, Walther-Antonio MR, Olayemi OO, 681
 et al. Lactobacillus crispatus thrives in pregnancy hormonal milieu in a Nigerian 682
 patient cohort. Scientific Reports. 2021;11(1):18152.
- [50] Ravel J, Brotman RM, Gajer P, Ma B, Nandy M, Fadrosh DW, et al. Daily temporal dynamics of vaginal microbiota before, during and after episodes of bacterial vaginosis.
 Microbiome. 2013;1(1):1–6.
- [51] Fethers KA, Fairley CK, Hocking JS, Gurrin LC, Bradshaw CS. Sexual risk factors 687
 and bacterial vaginosis: a systematic review and meta-analysis. Clinical Infectious 688
 Diseases. 2008;47(11):1426–1435. 689
- [52] Liao Y, Tong XT, Jia YJ, Liu QY, Wu YX, Xue WQ, et al. The effects of alco hol drinking on oral microbiota in the Chinese population. International Journal of
 Environmental Research and Public Health. 2022;19(9):5729.

- [53] Froehle L, Ghanem KG, Page K, Hutton HE, Chander G, Hamill MM, et al. Bacterial vaginosis and alcohol consumption: a cross-sectional retrospective study in Baltimore, Maryland. Sexually Transmitted Diseases. 2021;48(12):986–990.
- [54] Smart S, Singal A, Mindel A. Social and sexual risk factors for bacterial vaginosis.
 696
 Sexually Transmitted Infections. 2004;80(1):58–62.
- [55] Thorsen P, Vogel I, Molsted K, Jacobsson B, Arpi M, Møller BR, et al. Risk factors for
 bacterial vaginosis in pregnancy: a population-based study on Danish women. Acta
 Obstetricia et Gynecologica Scandinavica. 2006;85(8):906–911.
- [56] Shoubnikova M, Hellberg D, Nilsson S, Mårdh PA. Contraceptive use in women with the bacterial vaginosis. Contraception. 1997;55(6):355–358.
- [57] Rugpao S, Sriplienchan S, Rungruengthanakit K, Lamlertkittikul S, Pinjareon S, Wer awatakul Y, et al. Risk factors for bacterial vaginosis incidence in young adult Thai
 women. Sexually Transmitted Diseases. 2008;35(7):643–648.
- [58] Baisley K, Changalucha J, Weiss HA, Mugeye K, Everett D, Hambleton I, et al. 706
 Bacterial vaginosis in female facility workers in north-western Tanzania: prevalence 707
 and risk factors. Sexually Transmitted Infections. 2009;85(5):370–375. 708
- [59] Francis SC, Looker C, Vandepitte J, Bukenya J, Mayanja Y, Nakubulwa S, et al. Bac terial vaginosis among women at high risk for HIV in Uganda: high rate of recurrent
 diagnosis despite treatment. Sexually Transmitted Infections. 2016;92(2):142–148.

- [60] Cu-Uvin S, Hogan JW, Warren D, Klein RS, Peipert J, Schuman P, et al. 712
 Prevalence of lower genital tract infections among human immunodeficiency virus 713
 (HIV)—seropositive and high-risk HIV-seronegative women. Clinical Infectious Dis-714
 eases. 1999;29(5):1145–1150. 715
- [61] French AL, Adeyemi OM, Agniel DM, Evans CT, Yin MT, Anastos K, et al. The 716
 association of HIV status with bacterial vaginosis and vitamin D in the United States. 717
 Journal of Women's Health. 2011;20(10):1497–1503. 718
- [62] Brotman RM, Ghanem KG, Klebanoff MA, Taha TE, Scharfstein DO, Zenilman JM.
 The effect of vaginal douching cessation on bacterial vaginosis: a pilot study. American
 Journal of Obstetrics and Gynecology. 2008 Jun;198(6):628.e1–628.e7.
- [63] Sobel JD, Sobel R. Current and emerging pharmacotherapy for recurrent bacterial vaginosis. Expert Opinion on Pharmacotherapy. 2021;22(12):1593–1600.
- [64] Morsli M, Gimenez E, Magnan C, Salipante F, Huberlant S, Letouzey V, et al. 724
 The association between lifestyle factors and the composition of the vaginal micro-725
 biota: a review. European Journal of Clinical Microbiology & Infectious Diseases. 726
 2024;43(10):1869–1881. 727
- [65] Zhou X, Brown CJ, Abdo Z, Davis CC, Hansmann MA, Joyce P, et al. Differences 728
 in the composition of vaginal microbial communities found in healthy Caucasian and 729
 black women. ISME J. 2007;1(2):121–133.

- [66] Fettweis JM, Brooks JP, Serrano MG, Sheth NU, Girerd PH, Edwards DJ, et al. Differences in vaginal microbiome in African American women versus women of European
 ancestry. Microbiology. 2014;160(Pt 10):2272.
- [67] Borgdorff H, Veer Cvd, Houdt Rv, Alberts CJ, Vries HJd, Bruisten SM, et al. The 734 association between ethnicity and vaginal microbiota composition in Amsterdam, the 735 Netherlands. PLOS ONE. 2017;12(7):e0181135.
- [68] Lambert JA, John S, Sobel JD, Akins RA. Longitudinal analysis of vaginal microbiome 737
 dynamics in women with recurrent bacterial vaginosis: recognition of the conversion 738
 process. PLOS ONE. 2013;8(12):e82599. 739
- [69] Srinivasan S, Liu C, Mitchell CM, Fiedler TL, Thomas KK, Agnew KJ, et al. Temporal 740
 variability of human vaginal bacteria and relationship with bacterial vaginosis. PLOS 741
 ONE. 2010;5(4):e10197. 742
- [70] Armstrong E, Hemmerling A, Joag V, Huibner S, Kulikova M, Crawford E, et al. 743
 Treatment success following standard antibiotic treatment for bacterial vaginosis is 744
 not associated with pre-treatment genital immune or microbial parameters. Open 745
 Forum Infectious Diseases. 2023 Jan;p. ofad007. 746
- [71] Lebeer S, Ahannach S, Gehrmann T, Wittouck S, Eilers T, Oerlemans E, et al. A r47
 citizen-science-enabled catalogue of the vaginal microbiome and associated factors. r48
 Nature Microbiology. 2023;8(11):2183–2195. r49

- [72] Symul L, Jeganathan P, Costello EK, France M, Bloom SM, Kwon DS, et al. Sub communities of the vaginal microbiota in pregnant and non-pregnant women. Pro ceedings of the Royal Society B. 2023;290(2011):20231461.
- [73] Holm JB, France MT, Gajer P, Ma B, Brotman RM, Shardell M, et al. Integrating 753
 compositional and functional content to describe vaginal microbiomes in health and 754
 disease. Microbiome. 2023;11(1):259.
- [74] Brotman RM, Shardell MD, Gajer P, Tracy JK, Zenilman JM, Ravel J, et al. Interplay
 between the temporal dynamics of the vaginal microbiota and human papillomavirus
 detection. Journal of Infectious Diseases. 2014;210(11):1723–1733.

759

760

761

762

763

764

765

766

767

768

769

770

771

Supplementary Information

Competing interests SAlizon is a recommender for PCI Evolutionary Biology and PCI Ecology. JReynes reports personal fees from Gilead (payment or honoraria for lectures, presentations, or educational events) Merck (payment or honoraria for lectures, presentations, or educational events), Moderna (honoraria for lectures, or manuscript writing), Shionogi (honoraria for presentation) and ViiV Healthcare (consulting and payment or honoraria for lectures, presentations, or educational events) and support for attending meetings and/or travel from Gilead and Pfizer, all outside of the submitted work. JRavel is co-founder of LUCA Biologics, a biotechnology company focusing on translating microbiome research into live biotherapeutics drugs for women's health. He is Editorin-Chief at *Microbiome*. None of the other authors report any conflict of interest.

S1: Pairwise correlations between covariates

There were no strong correlations among covariates, with the strongest correlation found $_{773}$ between BMI and stress (r = 0.41; Fig. S1). $_{774}$



Figure S1: Correlation between covariates. Pairwise Pearson's correlation coefficients between covariates. Parameter descriptions are found in Materials and Methods.

S2: Assessment of posterior accuracy, precision and prior contraction 775

We leveraged the properties of posterior distributions to identify potential model fitting problems that might manifest from our model assumptions. To examine the accuracy and precision of posterior distributions, we first generated simulated observations based on the estimated posterior mean parameters. We then refitted our model to the simulated observations (i.e., secondary fitting) to compute the posterior z-score for each parameter, which measures how closely the posterior recovers the parameters of the data generating process [48]:

$$z = \frac{\mathbb{E}_{\rm sim} - \mathbb{E}_{\rm post}}{\sigma_{\rm sim}},$$

where \mathbb{E}_{post} denotes the posterior mean of the fit to the actual data that we consider the 'true' parameter. \mathbb{E}_{sim} and σ_{sim} denote the mean and standard deviation of the posterior distribution of the secondary fitting. The smaller the z-score, the closer the bulk of the posterior is to the true parameter [48]. In contrast, large z-values may be indicative of overfitting and, or poor prior specifications [48]. 780

To examine the influence of the likelihood function in relation to prior information, we computed the posterior contraction, k:

$$k = 1 - \frac{\sigma_{\text{post}}^2}{\sigma_{\text{prior}}^2}$$

where σ_{post}^2 and σ_{prior}^2 correspond to the variance of posterior and prior distributions, ⁷⁸¹ respectively. The *k* values close to zero indicate that data contain little information (i.e., ⁷⁸² rendering priors strongly informative). Conversely, values close to 1 indicate that data are ⁷⁸³ much more informative than the prior [48]. ⁷⁸⁴

We found that most of our model parameters and hyperparameters — were estimated 785 with accuracy, precision, and identifiability, with the absolute posterior z-scores below three 786 (Fig. S2). The posterior distributions for covariate coefficients, β , contracted by 86% on 787 average, and at least 75%, compared to the prior distribution, meaning that the covariate 788 coefficients were well-identified from data (Fig. S2). Although we used generic priors 789 recommended by Stan [42], the L_s parameters that define correlations among between-790 woman variation showed limited posterior contraction (i.e., $\leq \sim 0.25$), indicating that these 791 parameters are poorly informed by data. As such, we refrain from making biological 792 inferences about these correlations. 793

S3: Predicted difference in community state type (CST) prevalence at 794 various counterfactual scenarios.

Our counterfactual simulations predicted that alcohol consumption and the number of 796 partners are factors that impact the population-level outcome in terms of the prevalence 797 of different community state types. The full list of comparisons is available in Fig. S3. 798



Figure S2: Accuracy, precision and identifiability of estimated parameters. Posterior z-score (y-axis) measures how closely the posterior recovers the parameters of the true data-generating process and posterior contraction (x-axis) evaluates the influence of the likelihood function over the prior, respectively. Smaller absolute posterior z-scores indicate that the posterior accurately recovers the parameters of the data-generating process: the absolute value beyond three to four may indicate substantial bias [48]. The posterior contraction values close to one indicate that data are much more informative than the prior. The estimated parameters are represented by a filled dot.



Figure S3: Difference in community state type (CST) prevalence at predicted various counterfactual scenarios. The differences were calculated from posterior samples simulated at 0 and 1 for binary variables and at the population maximum and minimum values recorded by the PAPCLEAR for continuous variables (left panel). Additional differences were computed between the population maximum and mean (middle panel) and the population mean and minimum for continuous variables (right panel). Parameter descriptions are found in Materials and Methods.